1. Home
  2. BETA vs PRAX Comparison

BETA vs PRAX Comparison

Compare BETA & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BETA

Beta Technologies Inc.

N/A

Current Price

$20.02

Market Cap

7.0B

Sector

Industrials

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$308.49

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BETA
PRAX
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
9.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BETA
PRAX
Price
$20.02
$308.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
15
Target Price
$37.88
$572.13
AVG Volume (30 Days)
1.1M
328.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,051.11
$6,395.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.64
$26.70
52 Week High
$36.43
$354.87

Technical Indicators

Market Signals
Indicator
BETA
PRAX
Relative Strength Index (RSI) 49.12 43.37
Support Level $15.64 $290.36
Resistance Level $20.90 $322.32
Average True Range (ATR) 1.48 19.36
MACD 0.50 -4.96
Stochastic Oscillator 55.97 26.43

Price Performance

Historical Comparison
BETA
PRAX

About BETA Beta Technologies Inc.

BETA Technologies Inc is an aerospace company manufacturing electric flight. It designs, manufactures and sells high-performance electric aircraft, advanced electric propulsion systems, charging systems and components. The company has one operating and reportable segment - Development and Manufacturing Electric Aircrafts. Its products include: Aircraft, Charge, Motor, Battery, and Flight Controls.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: